Effect of Thyroid Hormone on Urinary Excretion of Epidermal Growth Factor

1997 ◽  
Vol 29 (3) ◽  
pp. 222-228 ◽  
Author(s):  
S.M. Huang ◽  
S.H. Chan ◽  
T.J. Wu ◽  
N.H. Chow
1990 ◽  
Vol 31 (2) ◽  
pp. 115-124 ◽  
Author(s):  
Per E. Jørgensen ◽  
Lasse Raaberg ◽  
Steen Seier Poulsen ◽  
Ebba Nexø

Author(s):  
Jon Viljar Norvik ◽  
Laura R Harskamp ◽  
Viji Nair ◽  
Kerby Shedden ◽  
Marit D Solbu ◽  
...  

Abstract Background Lower urinary excretion of the kidney tubule–specific biomarker epidermal growth factor (uEGF) is associated with increased risk of renal function [glomerular filtration rate (GFR)] loss in diabetes and in patients with established chronic kidney disease (CKD). We investigated whether uEGF is associated with rapid GFR decline or incident CKD in the general population. Methods Subjects without CKD or diabetes were recruited from the general population in Tromso, Norway [Renal Iohexol Clearance Survey (RENIS); N = 1249] and Groningen, the Netherlands [Prevention of REnal and Vascular END-stage disease (PREVEND); N = 4534], with a median follow-up of 5.6 and 7.4 years, respectively. GFR was measured by iohexol clearance in the RENIS and estimated using the CKD Epidemiology Collaboration creatinine–cystatin C equation in the PREVEND study. Rapid GFR decline was defined as an annual GFR loss >3.0 mL/min/1.73 m2 and in sensitivity analyses as subjects with the 10% steepest GFR slope within each cohort. Results Lower baseline uEGF excretion was associated with rapid GFR loss in both cohorts {RENIS, odds ratio [OR] per 1 μg/mmol lower uEGF 1.42 [95% confidence interval (CI) 1.06–1.91], P = 0.02; PREVEND, OR 1.29 [95% CI 1.10–1.53], P < 0.01}, adjusted for baseline GFR, albumin:creatinine ratio and conventional CKD risk factors. Similar results were obtained using the outcome of the 10% steepest GFR slope in each cohort. Lower uEGF levels were associated with incident CKD in the combined analysis of both cohorts. Conclusions Lower uEGF levels are associated with increased risk of rapid GFR loss and incident CKD in the general population. This finding, together with previous findings in CKD and high-risk populations, supports that uEGF may serve as a broadly applicable biomarker representing the tubular component of the current glomerulus-centric clinical risk assessment system.


1991 ◽  
Vol 11 (4) ◽  
pp. 313-317 ◽  
Author(s):  
Paolo Madeddu ◽  
Pasquale Ena ◽  
Paolo Pinna Parpaglia ◽  
Giovanna Patteri ◽  
Sofia Bacciu ◽  
...  

1994 ◽  
Vol 7 (2) ◽  
pp. 127-130 ◽  
Author(s):  
José A. Amado ◽  
Angel L. M. De-Francisco ◽  
Manuel A. Botana ◽  
Carlos Pesquera ◽  
José A. Vázquez-de-Prada ◽  
...  

Endocrinology ◽  
2007 ◽  
Vol 149 (2) ◽  
pp. 695-702 ◽  
Author(s):  
Gianluca Canettieri ◽  
Antonella Franchi ◽  
Michele Della Guardia ◽  
Ianessa Morantte ◽  
Maria Giulia Santaguida ◽  
...  

Human type II deiodinase is a master regulator of thyroid hormone activation in several tissues. In placenta, type II deiodinase mRNA levels and enzymatic activity are elevated only during the first trimester of pregnancy and then progressively decline. During this early stage, mitogens such as epidermal growth factor (EGF) have been shown to promote the proliferation of the trophoblast by acting through multiple mechanisms. Here we show that EGF modulates transcription of human type II deiodinase gene (Dio2) through distinct signaling pathways, leading to the assembly of a heterogeneous transcription factor complex. Gene expression and deiodination assays have shown that EGF promptly induces a short-lived Dio2 mRNA and enzymatic activity. The induction is mediated by ERK and p38 kinases, as demonstrated by selective inhibition or overexpression of different mitogen-activated kinases. Reporter assays of mutant constructs indicate that EGF-induced transcriptional activity on Dio2 promoter is mediated by the cAMP response element (CRE) and does not involve the activating protein 1 site. With functional and biochemical approaches, we have demonstrated that the EGF stimulation culminates with the assembly and recruitment over the Dio2 CRE of a composite complex, which consists of c-Jun, c-Fos, and CRE-binding protein. These results further support the hypothesis that placental iodothyronine metabolism is critical during early pregnancy.


1999 ◽  
Vol 338 (2) ◽  
pp. 427-432 ◽  
Author(s):  
Hung-Yun LIN ◽  
Ai SHIH ◽  
Faith B. DAVIS ◽  
Paul J. DAVIS

We have examined the effects of l-thyroxine (T4) on the activation of signal transducer and activator of transcription 3 (STAT3) and on the STAT3-dependent induction of c-Fos expression by epidermal growth factor (EGF). T4, at a physiological concentration of 100 nM, caused tyrosine phosphorylation and nuclear translocation (i.e. activation) of STAT3 in HeLa cells in as little as 10–20 min. Activation by T4 of STAT3 was maximal at 30 min (15±4-fold enhancement; mean±S.E.M.) in 18 experiments. This effect was reproduced by T4–agarose (100 nM) and blocked by CGP 41251, genistein, PD 98059 and geldanamycin, inhibitors of protein kinase C (PKC), protein tyrosine kinase (PTK), mitogen-activated protein kinase (MAPK) kinase and Raf-1 respectively. Tyrosine-phosphorylated MAPK also appeared in nuclear fractions within 10 min of treatment with T4. In the nuclear fraction of T4-treated cells, MAPK immunoprecipitate also contained STAT3. The actions of T4 were similar in HeLa and CV-1 cells, which lack thyroid hormone receptor (TR), and in TR-replete skin fibroblasts (BG-9). T4 also potentiated the EGF-induced nuclear translocation of activated STAT1α and STAT3 and enhanced the EGF-stimulated expression of c-Fos. Hormone potentiation of EGF-induced signal transduction and c-Fos expression was inhibited by CGP 41251, geldanamycin and PD 98059. Therefore the non-genomically induced activation by T4 of STAT3, and the potentiation of EGF by T4, require activities of PKC, PTK and an intact MAPK pathway.


Sign in / Sign up

Export Citation Format

Share Document